CMND Stock Risk & Deep Value Analysis

Clearmind Medicine Inc

DVR Score

0.5

out of 10

Distressed

The Bottom Line on CMND

We analyzed Clearmind Medicine Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran CMND through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Mar 15, 2026•Run Fresh Analysis →

📈CMND Performance Overview3yr weekly

📊

Unlock CMND Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

CMND Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

High

Market Risk

High

CMND Deep Value Analysis

Clearmind Medicine operates in the promising psychedelic therapeutics market, with a compelling vision for its non-hallucinogenic MEAI to treat AUD. The addressable market is significant, and the science holds potential. However, the company continues to exhibit catastrophic financial distress. The stated '$0.00B' market cap at a price of $0.78 (down from $1.12 previously) indicates severe insolvency, imminent delisting, or a near-complete wipeout of common equity value. This financial state completely overshadows any scientific promise, making long-term growth, let alone 10x, impossible for current shareholders within the 3-5 year timeframe. The fundamental issues outlined in the previous analysis persist, rendering it a 'dud' due to terminal financial limitations.

CMND Red Flags & Warning Signs

Premium

⚠
Delisting from exchange due to non-compliance
⚠
Bankruptcy filing or liquidation announcement
⚠
Further dilutive equity offerings without significant progress
⚠
Negative clinical trial results or regulatory setbacks

Unlock CMND Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

CMND Competitive Moat Analysis

Premium

Moat Rating

None

Moat Trend

Eroding

Moat Sources

1 Identified

Intangible Assets/IP (theoretical, but currently uncommercializable)

While the company may possess some intellectual property, its severe financial distress and inability to fund operations or trials renders any potential moat non-durable and effectively non-existent. Without financial viability, IP cannot be defended or commercialized.

CMND Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

CMND Catalysts & Growth Drivers

Near-Term (0-6 months)

•Announcement of successful (non-dilutive) financing round or strategic partnership
•Positive clinical trial data for MEAI (likely overshadowed by financial distress)

Medium-Term (6-18 months)

•Significant debt restructuring or bankruptcy reorganization leading to a new entity
•Regulatory clarity or Fast Track designation for MEAI

Long-Term (18+ months)

•Commercialization success of MEAI, potentially under new ownership or after severe restructuring
•Broader adoption of psychedelic-inspired therapeutics

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

CMND Bull Case: What Could Go Right

✓
Announcement of non-dilutive, significant institutional funding
✓
Successful resolution of all debt obligations and going concern warnings
✓
Reversal of delisting threat or successful uplisting
✓
Any further dilution or lack of funding progress (negative signal)

Bull Case Analysis

See what could go right with Premium

🔔

Never miss a move on CMND

Create a free account to set price alerts and get notified on Telegram when CMND hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Clearmind Medicine Inc (CMND)?

As of March 15, 2026, Clearmind Medicine Inc has a DVR Score of 0.5 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the risk level for CMND stock?

Our analysis rates Clearmind Medicine Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

How often is the CMND DVR analysis updated?

Our AI-powered analysis of Clearmind Medicine Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 15, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.